AKT1 and rheumatoid arthritis: A total of 18 possible components and 34 core targets were obtained by network pharmacology, among which inflammatory response, phosphatidylinositide 3‐kinases (PI3K)‐AKT and MAPK pathways were involved in the therapeutic effect of TY on RA.